Compound: LYNESTRENOL
SMILES: O[C@]1(C#C)[C@@]2([C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1)C
InChIKey: YNVGQYHLRCDXFQ-XGXHKTLJSA-N
Synonyms: LYNESTRENOL, 52-76-6, Linestrenol, Ethinylestrenol, Lynoestrenol, Orgametril, Ethynylestrenol, Orgametil, 3-Desoxynorlutin, NSC-37725, Linestrenolo, Lynestrenolum, 17alpha-Ethynylestrenol, DTXSID4021478, 19-Nor-17alpha-pregn-4-en-20-yn-17-ol, N2Z8ALG4U5, NSC37725, 19-norpregn-4-en-20-yn-17alpha-ol, DTXCID501474457, Linesterol, RefChem:800197, G03AC02, G03DC03, 200-151-4, Orgametrol, Exluton, Exlutona, Endometril, Exlution, Org 485-50, IND 1006, MFCD00051135, 17.alpha.-Ethynylestrenol, (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol, Exluten, 17alpha-Ethynyl-19-nor-4-androsten-17beta-ol, 19-Norpregn-4-en-20-yn-17-ol, (17a)-, 19-Norpregn-4-en-20-yn-17-ol, (17.alpha.)-, Ethynloestrenol, Estr-4-en-17.beta.-ol, 17-ethynyl-, Lynenol, Lynstranol, Ethinyloestranol, Ethinyl oestrenol, 19-Norpregn-4-en-20-yn-17-ol, (17alpha)-, 19-Nor-17.alpha.-pregn-4-en-20-yn-17-ol, .DELTA.4-17.alpha.-Ethinylestren-17.beta.-ol, Linestrenolo [DCIT], 17-alpha-Ethynylestrenol, 17-alpha-Ethynyloestrenol, Linestrenol [INN-Spanish], Lynestrenolum [INN-Latin], CCRIS 9093, EINECS 200-151-4, Lynoestrenol [Progestins], NSC 37725, Estr-4-en-17beta-ol, 17-ethynyl-, UNII-N2Z8ALG4U5, 17-alpha-Ethynylestr-4-en-17-beta-ol, delta4-17alpha-Ethinylestren-17beta-ol, 17-alpha-Ethynyloestr-4-en-17-beta-ol, Lynestrenol CRS, 17-alpha-Ethinyl-17-beta-hydroxyestr-4-ene, 17-alpha-Ethinyl-17-beta-hydroxyoestr-4-ene, HSDB 7899, 17-alpha-Ethynil-delta-4-estrene-17-beta-ol, (17-alpha)-19-Norpregn-4-en-20-yn-17-ol, CAS-52-76-6, delta(sup 4)-17-alpha-Ethinylestren-17-beta-ol, NCGC00016233-01, (1R,3aS,3bR,9aR,9bS,11aS)-1-ethynyl-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-ol, delta(sup 4)-17-alpha-Ethinyloestren-17-beta-ol, Lynestrenol [USAN:INN:BAN:JAN], Prestwick_533, NSC-73879, LYNESTRENOL [MI], Prestwick0_000095, Prestwick1_000095, Prestwick2_000095, Prestwick3_000095, LYNESTRENOL [INN], LYNESTRENOL [JAN], Lynestrenol (JAN/USAN), LYNESTRENOL [USAN], 19-Nor-17-alpha-pregn-4-en-20-yn-17-ol, LYNESTRENOL [MART.], 19 Norpregn-4-en-20-yn-17-ol, (17alpha)-, SCHEMBL37816, BSPBio_000050, LYNESTRENOL [USP-RS], LYNESTRENOL [WHO-DD], SPBio_001989, 17-Ethynylestr-4-en-17-ol, BPBio1_000056, CHEMBL2107431, CHEBI:31790, HMS1568C12, HMS2095C12, HMS3712C12, LYNESTRENOL [EP MONOGRAPH], NSC73879, Tox21_110319, Tox21_301969, LMST02030127, s4883, AKOS024462708, Tox21_110319_1, 19-Nor-4-pregnen-20-yn-17beta-ol, CCG-220095, DB12474, FL35098, Lynestrenol for peak identification CRS, MSK161816-100A, NCGC00179676-01, NCGC00179676-03, NCGC00255262-01, 17alpha-19-Norpregn-4-en-20-yn-17-ol, CS-0032008, L0246, NS00003323, 17|A-Ethynyl-19-nor-4-androsten-17|A-ol, C75475, D01580, Lynestrenol Solution in Acetonitrile, 100ug/mL, Q2071071, BRD-K39707084-001-04-1, BRD-K39707084-001-05-8, 19 NORPREGN-4-EN-20-YN-17-OL, (17.ALPHA.)-, Lynestrenol Working Standard (Secondary Reference Standard), (8R,9S,10R,13S,14S,17R)-17-ethynyl-13-methyl-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol
Theoretical properties:
molecular_formula: C20H28O
molecular_weight: 284.4 g/mol
exact_mass: 284.214015512 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 1
rotatable_bond_count: 1
heavy_atom_count: 21
topological_polar_surface_area: 20.2 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: Solid
color: Solid
melting_point: 158-160 °C
Descriptions:
pubchem: Lynestrenol can cause cancer according to The World Health Organization's International Agency for Research on Cancer (IARC).
chembl: LYNESTRENOL is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Lynestrenol, sold under the brand names Exluton and Ministat among others, is a progestin medication which is used in birth control pills and in the treatment of gynecological disorders. The medication is available both alone and in combination with an estrogen. It is taken by mouth.
Lynestrenol is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak androgenic and estrogenic activity and no other important hormonal activity. The medication is a prodrug of norethisterone in the body, with etynodiol occurring as an intermediate.
Lynestrenol was discovered in the late 1950s and was introduced for medical use in 1961. It has mostly been used in Europe and elsewhere in the world and was never marketed in the United States.